Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Neoplasms 2Lung Neoplasms 2Gliosarcoma 2Glioblastoma 2Carcinoma, Renal Cell 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Tuberculosis, Pulmonary 1Tongue Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Salivary Gland Neoplasms 1Rhabdoid Tumor 1Rectal Neoplasms 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Nasopharyngeal Neoplasms 1Multiple Myeloma 1Mouth Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Head and Neck Neoplasms 1HER2-positive Breast Cancer 1Esthesioneuroblastoma, Olfactory 1Endometrial Neoplasms 1Colonic Neoplasms 1Chordoma 1Breast Neoplasms, Male 1

Interventions

Trastuzumab 4pertuzumab 2Docetaxel 2palbociclib 1Protons 1Paclitaxel 1Letrozole 1Fulvestrant 1Fluorodeoxyglucose F18 1Enfuvirtide 1Doxorubicin 1Cyclophosphamide 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × HER2-positive Breast Cancer × Fluorodeoxyglucose F18 × Clear all
NCT04273555 2026-02-06

Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging

University of Alabama at Birmingham

Phase 1/2 Withdrawn
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡